宜宾整形医院双眼皮都在什么价位宜宾唇部脱毛医院,宜宾哪个医院去眼袋效果好,宜宾韩式开眼角哪好,宜宾割一个双眼皮恢复多久,宜宾玻尿酸隆鼻要住院吗,宜宾眼角整容,宜宾做丰胸那家美容机构好

BEIJING, Jan. 12 (Xinhua) -- China's consumer price index (CPI), a main gauge of inflation, rose 4.1 percent year-on-year in December, down 0.1 percentage point from November on falling non-food prices, the National Bureau of Statistics (NBS) said Thursday.The CPI was up 5.4 percent in 2011 from the previous year, well above the government's full-year inflation control target of 4 percent, the NBS said in a statement on its website.The inflation rate in December marked a five-straight-month decline after hitting a 37-month high of 6.5 percent in July amid government tightening measures, according to the NBS data.On a monthly basis, the cost of living dipped 0.2 percent in December, while prices of entertainment, educational and cultural articles and services dropped 0.3 percent, the NBS said.Food prices, which account for nearly one third of the basket of goods in the nation's CPI calculation, went up 9.1 percent year-on-year in December and 1.2 percent month-on-month, the NBS said.The December inflation figure was in line with the market expectation, as many economists forecast that the CPI would grow around 4 percent year-on-year in December.China's Producer Price Index (PPI), a major measure of inflation at the wholesale level, rose 1.7 percent in December year-on-year, further weakening from 2.7 a month earlier.China has made controlling prices a top priority last year and implemented a series of measures to address the issue, including tightening monetary policy, cracking down on speculation, increasing food supplies and reducing circulation costs.

WASHINGTON, Nov. 11 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved HEMACORD, the first licensed hematopoietic progenitor cells-cord cell therapy.HEMACORD is indicated for use in hematopoietic stem cell transplantation procedures in patients with disorders affecting the blood forming system. For example, cord blood transplants have been used to treat patients with certain blood cancers and some inherited metabolic and immune system disorders."The use of cord blood hematopoietic progenitor cell therapy offers potentially life-saving treatment options for patients with these types of disorders," said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement.HEMACORD contains hematopoietic progenitor cells (HPCs) from human cord blood. Cord blood is one of three sources of HPCs used in transplants. The other two are bone marrow and peripheral blood. Once these HPCs are infused into patients, the cells migrate to the bone marrow where they divide and mature. When the mature cells move into the bloodstream they can partially or fully restore the number and function of many blood cells, including immune function.

WASHINGTON, Dec. 7 (Xinhua) -- The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.Their report, published on-line Wednesday in Gynecologic Oncology, suggests that this combination, ixabepilone and sunitinib, might offer a much needed treatment option for women with advanced ovarian cancer.Neither drug is approved for use in ovarian cancer. Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it."Women die from ovarian cancer because their tumors become resistant to chemotherapy, so a drug that might be able to reduce that resistance -- which may be what this combination of agents is doing -- would be a boon to treatment of this difficult cancer," says study coauthor Gerardo Colon-Otero.The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by the drug duo. It might be a potential biomarker that may help identify patients who might benefit from such combination therapy, the researchers say.

BEIJING, Jan. 14 (Xinhua) -- A Spring Festival gala was held at the Great Hall of the People Saturday to entertain the country's military officers, soldiers and civilians.Representatives of officers and soldiers in the military units and armed police forces in Beijing as well as some Beijing residents attended the gala.President Hu Jintao and other top Chinese leaders including Wu Bangguo, Jia Qinglin, Li Changchun, Xi Jinping, Li Keqiang, He Guoqiang and Zhou Yongkang were also present at the gala.Hu expressed greetings to the audience and extended his good wishes for them, ahead of the traditional Spring Festival, or the Chinese Lunar New Year, which falls on Jan. 23 this year.